FMP
CNS Pharmaceuticals, Inc.
CNSP
NASDAQ
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
0.106 USD
0.0037 (3.5%)
InvestorPlace
Jul 30, 2024
CNS Pharmaceuticals (NASDAQ: CNSP ) stock is heading lower on Tuesday after the clinical-pharmaceutical company announced an expansion to its pipeline. CNS Pharmaceuticals has acquired an exclusive license and the intellectual property rights to TPI 287.
Accesswire
May 20, 2024
Live webcast fireside chat on Tuesday, May 21st at 1:40 PM ET HOUSTON, TX / ACCESSWIRE / May 20, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Gl...
Accesswire
Apr 23, 2024
Presentation on Monday, April 29th at 4:15 PM (GMT+1) HOUSTON, TX / ACCESSWIRE / April 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 4:15 PM (GMT+1) in London...
Accesswire
Apr 1, 2024
HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at two upcoming investor conferences being held in New York City in April. In addition to the presentations, management will be available to...
Benzinga
Feb 9, 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Accesswire
Sep 5, 2023
Live webcast presentation on Wednesday, September 13th at 10:30 AM ET HOUSTON, TX / ACCESSWIRE / September 5, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New Yor...
Accesswire
Jun 14, 2023
Live webcast fireside chat on Wednesday, June 21st at 2:30 PM ET HOUSTON, TX / ACCESSWIRE / June 14, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC ...
Accesswire
Apr 27, 2023
Live moderated video webcast with members of CNS Pharmaceuticals management on Wednesday, May 3rd at 12:00 PM ET HOUSTON, TX / ACCESSWIRE / April 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study on Wed...
PennyStocks
Apr 21, 2023
Use these tips for trading penny stocks efficiently The post Essential Penny Stock Trading Tools: Maximizing Efficiency appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Apr 17, 2023
Use these tips for researching penny stocks in 2023 The post Penny Stock Due Diligence: Top Research Techniques appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.